Shares of LB Pharmaceuticals Inc (NASDAQ:LBRX – Get Free Report) rose 8.2% during trading on Wednesday . BMO Capital Markets initiated coverage on shares of LB Pharmaceuticals in a research report on Monday, July 20th. According to MarketBeat, LB Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.43. Get LB Pharmaceuticals alerts:View Our Latest Analysis on LB PharmaceuticalsLB Pharmaceuticals Price PerformanceThe firm has a market capitalization of $1.07 billion and a price-to-earnings ratio of -21.58. LB Pharmaceuticals Company Profile(Get Free Report)We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.